[Skip to Content]
[Skip to Content Landing]
Article
December 1970

Recent Results in Cancer Research: Rubidomycin.

Author Affiliations

Washington, DC

 

Edited by J Bernard, MD; R Paul, MD; M Boiron, MD; Jacquillat, MD; and R Maral, MD. Price, $13.20. Pp 181, with 68 illustrations. Springer-Verlag Inc, 175 Fifth Ave, New York 10010, 1969.

Arch Intern Med. 1970;126(6):1079-1080. doi:10.1001/archinte.1970.00310120141031

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.

Abstract

This monograph contains a rather complete tabulation of the current data on a new antibiotic with antitumoral activity. This antibiotic known as Rubidomycin (Daunomycin, daunorubicin) was originally extracted from a strain of streptomyces and called Rubidomycin by the French. Almost concurrently the Italians extracted from another strain of streptomyces an identical antibiotic which they called Daunomycin. Daunorubicin occurs as a red, crystalline powder and belongs to the anthracycline group of glycoside antibiotics. Experimentally, the agent has antitumoral activity against a variety of animal sarcomas and carcinomas as well as leukemias and tumors of viral origin. The compound acts through its mitostatic ability which changes chromosome structure and disrupts the metabolism first of DNA and subsequently RNA.

Bernard, Paul, Boiron, Jacquillat, and Maral have divided their monograph into two major sections. The first deals with the preparation, structure, biological activity, mechanism of action, and toxicology of Daunorubicin. The second section

First Page Preview View Large
First page PDF preview
First page PDF preview
×